Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $225 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a $225 price target.
May 03, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital maintains a Buy rating on Alnylam Pharmaceuticals with a $225 price target.
The reaffirmation of a Buy rating and a high price target by a reputable analyst like Keay Nakae suggests a strong vote of confidence in Alnylam Pharmaceuticals. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in ALNY's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100